Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: Strong Impact Across Ejection Fraction Spectrum
- PMID: 37257949
- DOI: 10.1016/j.jacc.2023.04.006
Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: Strong Impact Across Ejection Fraction Spectrum
Keywords: acute heart failure; ejection fraction; heart failure; medical therapy; randomized trial.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Fonarow has served as a consultant for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Eli Lilly, Johnson & Johnson, Medtronic, Merck, Novartis, and Pfizer. Dr Greene has received research support from the Duke University Department of Medicine Chair’s Research Award, American Heart Association (#929502), Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim/Lilly, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, Sanofi, and scPharmaceuticals; has served as a consultant for Amgen, Bayer, Bristol Myers Squibb, Boehringer Ingelheim/Lilly, CSL Vifor, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from Boehringer Ingelheim, Cytokinetics, and Roche Diagnostics.
Comment on
-
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction.J Am Coll Cardiol. 2023 Jun 6;81(22):2131-2144. doi: 10.1016/j.jacc.2023.03.426. J Am Coll Cardiol. 2023. PMID: 37257948 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
